Effects of Risedronate in Runx2 Overexpressing Mice, an Animal Model for Evaluation of Treatment Effects on Bone Quality and Fractures

[1]  V. Geoffroy,et al.  Bone loss induced by Runx2 Over‐expression in mice is blunted by osteoblastic over‐expression of TIMP‐1 , 2010, Journal of cellular physiology.

[2]  R. Rizzoli,et al.  Selective Modification of Bone Quality by PTH, Pamidronate, or Raloxifene , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  L. Bachrach,et al.  Clinical review 1: Bisphosphonate use in childhood osteoporosis. , 2009, The Journal of clinical endocrinology and metabolism.

[4]  Julienne E. M. Brouwers,et al.  Determination of rat vertebral bone compressive fatigue properties in untreated intact rats and zoledronic-acid-treated, ovariectomized rats , 2008, Osteoporosis International.

[5]  G. Lyritis,et al.  The laboratory rat as an animal model for osteoporosis research. , 2008, Comparative medicine.

[6]  D. Burr,et al.  Review of Nonprimate, Large Animal Models for Osteoporosis Research , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  K. Kavanagh,et al.  Bisphosphonates , 2007, Annals of the New York Academy of Sciences.

[8]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[9]  V. Geoffroy,et al.  Overexpression of the transcriptional factor Runx2 in osteoblasts abolishes the anabolic effect of parathyroid hormone in vivo. , 2007, The American journal of pathology.

[10]  E. Seeman,et al.  Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. , 2007, Endocrine reviews.

[11]  M. Balooch,et al.  Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization. , 2006, Bone.

[12]  P. Geusens,et al.  Relationship Between Changes in BMD and Nonvertebral Fracture Incidence Associated With Risedronate: Reduction in Risk of Nonvertebral Fracture Is Not Related to Change in BMD , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  C. Cooper,et al.  Relationship Between Changes in Bone Mineral Density and Fracture Risk Reduction With Antiresorptive Drugs: Some Issues With Meta‐Analyses , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  K. Takaoka,et al.  Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. , 2003, Endocrinology.

[15]  R. Recker,et al.  Distribution of Collagen Cross‐Links in Normal Human Trabecular Bone , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  M. Bouxsein,et al.  Bone quality: where do we go from here? , 2003, Osteoporosis International.

[17]  M. Kassem,et al.  Effect of Hormone Replacement Therapy on Bone Quality in Early Postmenopausal Women , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  D. Burr,et al.  Bone Mineral and Collagen Quality in Humeri of Ovariectomized Cynomolgus Monkeys Given rhPTH(1–34) for 18 Months , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  A. Boyde,et al.  High Bone Resorption in Adult Aging Transgenic Mice Overexpressing Cbfa1/Runx2 in Cells of the Osteoblastic Lineage , 2002, Molecular and Cellular Biology.

[20]  Fran Harris,et al.  Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. , 2002, The American journal of medicine.

[21]  M. Meredith,et al.  A method to assess the proportion of treatment effect explained by a surrogate endpoint , 2001, Statistics in medicine.

[22]  R Mendelsohn,et al.  Spectroscopic Characterization of Collagen Cross‐Links in Bone , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  N. Kanatani,et al.  Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures , 2001, The Journal of cell biology.

[24]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[25]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[26]  A J Bailey,et al.  Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. , 1998, Bone.

[27]  A. Bailey,et al.  Chemistry of collagen cross-linking: biochemical changes in collagen during the partial mineralization of turkey leg tendon. , 1997, The Biochemical journal.

[28]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[29]  L. Mosekilde.  Assessing bone quality--animal models in preclinical osteoporosis research. , 1995, Bone.

[30]  L. Kurth,et al.  Identification of the loci of the collagen-associated Ehrlich chromogen in type I collagen confirms its role as a trivalent cross-link. , 1992, The Biochemical journal.

[31]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  D. Chappard,et al.  Strontium ranelate decreases the incidence of new caudal vertebral fractures in a growing mouse model with spontaneous fractures by improving bone microarchitecture , 2010, Osteoporosis International.

[33]  T. Arnett,et al.  Inhibition of osteoblast function in vitro by aminobisphosphonates , 2009, Journal of cellular biochemistry.

[34]  John Adams.  Assessing , 2020, Transport Planning.

[35]  S. Boonen,et al.  The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. , 2005, Clinical therapeutics.

[36]  T. Hefferan,et al.  Animal Models For Osteoporosis , 2004, Reviews in Endocrine and Metabolic Disorders.

[37]  A. Bailey,et al.  Biochemical changes in the collagen of human osteoporotic bone matrix. , 1993, Connective tissue research.